Literature DB >> 25403668

16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

E Amram1, I Mikula2, C Schnee3, R D Ayling4, R A J Nicholas4, R S Rosales4, S Harrus5, I Lysnyansky6.   

Abstract

Mycoplasma bovis isolates with decreased susceptibilities to tetracyclines are increasingly reported worldwide. The acquired molecular mechanisms associated with this phenomenon were investigated in 70 clinical isolates of M. bovis. Sequence analysis of the two 16S rRNA-encoding genes (rrs3 and rrs4 alleles) containing the primary binding pocket for tetracycline (Tet-1 site) was performed on isolates with tetracycline hydrochloride MICs of 0.125 to 16 μg/ml. Mutations at positions A965T, A967T/C (Escherichia coli numbering) of helix 31, U1199C of helix 34, and G1058A/C were identified. Decreased susceptibilities to tetracycline (MICs, ≥2 μg/ml) were associated with mutations present at two (A965 and A967) or three positions (A965, A967, and G1058) of the two rrs alleles. No tet(M), tet(O), or tet(L) determinants were found in the genome of any of the 70 M. bovis isolates. The data presented correlate (P<0.0001) the mutations identified in the Tet-1 site of clinical isolates of M. bovis with decreased susceptibility to tetracycline.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25403668      PMCID: PMC4335885          DOI: 10.1128/AAC.03876-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Complete genome sequence of Mycoplasma bovis type strain PG45 (ATCC 25523).

Authors:  Kim S Wise; Michael J Calcutt; Mark F Foecking; Kerstin Röske; Ramana Madupu; Barbara A Methé
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

2.  Antimicrobial susceptibility pattern of Brachyspira intermedia isolates from European layers.

Authors:  Marc Verlinden; Filip Boyen; Frank Pasmans; An Garmyn; Freddy Haesebrouck; An Martel
Journal:  Microb Drug Resist       Date:  2011-06-11       Impact factor: 3.431

3.  Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum.

Authors:  Ken B Waites; Lynn B Duffy; Cécile M Bébéar; Anne Matlow; Deborah F Talkington; George E Kenny; Patricia A Totten; Donald J Bade; Xiaotian Zheng; Maureen K Davidson; Virginia D Shortridge; Jeffrey L Watts; Steven D Brown
Journal:  J Clin Microbiol       Date:  2012-08-22       Impact factor: 5.948

4.  Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by Mycoplasma bovis.

Authors:  Uri Lerner; Eytan Amram; Roger D Ayling; Inna Mikula; Irena Gerchman; Shimon Harrus; Dina Teff; David Yogev; Inna Lysnyansky
Journal:  Vet Microbiol       Date:  2013-12-14       Impact factor: 3.293

5.  In vitro antimicrobial inhibition of Mycoplasma bovis isolates submitted to the Pennsylvania Animal Diagnostic Laboratory using flow cytometry and a broth microdilution method.

Authors:  Marty K Soehnlen; M Elaine Kunze; K Eranda Karunathilake; Brittnee M Henwood; Subhashinie Kariyawasam; David R Wolfgang; Bhushan M Jayarao
Journal:  J Vet Diagn Invest       Date:  2011-05       Impact factor: 1.279

6.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

7.  Antimicrobial susceptibilities of four species of Mycoplasma isolated in 2008 and 2009 from cattle in Japan.

Authors:  Ryoko Uemura; Masuo Sueyoshi; Hiroshi Nagatomo
Journal:  J Vet Med Sci       Date:  2010-08-11       Impact factor: 1.267

8.  Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.

Authors:  Michael L Beeton; Victoria J Chalker; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  Comparative geno-plasticity analysis of Mycoplasma bovis HB0801 (Chinese isolate).

Authors:  Jingjing Qi; Aizhen Guo; Peng Cui; Yingyu Chen; Riaz Mustafa; Xiaoliang Ba; Changmin Hu; Zhidi Bai; Xi Chen; Lei Shi; Huanchun Chen
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

10.  The complete genome sequence of Mycoplasma bovis strain Hubei-1.

Authors:  Yuan Li; Huajun Zheng; Yang Liu; Yanwei Jiang; Jiuqing Xin; Wei Chen; Zhiqiang Song
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

View more
  14 in total

1.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 2.  Tetracycline Antibiotics and Resistance.

Authors:  Trudy H Grossman
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

3.  A GC-Rich Prophage-Like Genomic Region of Mycoplasma bovirhinis HAZ141_2 Carries a Gene Cluster Encoding Resistance to Kanamycin and Neomycin.

Authors:  Inna Lysnyansky; Ilya Borovok
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment.

Authors:  Teck-Phui Chua; Jennifer Danielewski; Kaveesha Bodiyabadu; Catriona S Bradshaw; Dorothy A Machalek; Suzanne M Garland; Erica L Plummer; Lenka A Vodstrcil; Gerald L Murray
Journal:  Antimicrob Agents Chemother       Date:  2022-04-14       Impact factor: 5.938

5.  Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyclines, and Spectinomycin.

Authors:  Eiji Hata; Takehiro Harada; Megumi Itoh
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

6.  High Prevalence of Diverse Insertion Sequences within the rRNA Operons of Mycoplasma bovis.

Authors:  Eytan Amram; Ilya Borovok; Yaarit Nachum-Biala; Roger Ayling; Uri Lerner; Shimon Harrus; Inna Lysnyansky
Journal:  Appl Environ Microbiol       Date:  2016-10-14       Impact factor: 4.792

Review 7.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

8.  The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome.

Authors:  Corina G Heidrich; Sanya Mitova; Andreas Schedlbauer; Sean R Connell; Paola Fucini; Judith N Steenbergen; Christian Berens
Journal:  Antibiotics (Basel)       Date:  2016-09-22

9.  Antimicrobial Sensitivity Testing of Mycoplasma bovis Isolates Derived from Western Canadian Feedlot Cattle.

Authors:  Murray Jelinski; Andrea Kinnear; Karen Gesy; Sara Andrés-Lasheras; Rahat Zaheer; Scott Weese; Tim A McAllister
Journal:  Microorganisms       Date:  2020-01-16

10.  Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.

Authors:  Shinya Goto; Satoru Konnai; Yuki Hirano; Junko Kohara; Tomohiro Okagawa; Naoya Maekawa; Yamato Sajiki; Kei Watari; Erina Minato; Atsuhi Kobayashi; Satoshi Gondaira; Hidetoshi Higuchi; Masateru Koiwa; Motoshi Tajima; Eiji Taguchi; Ryoko Uemura; Shinji Yamada; Mika K Kaneko; Yukinari Kato; Keiichi Yamamoto; Mikihiro Toda; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Front Vet Sci       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.